

Randal H Henderson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3228920/publications.pdf>

Version: 2024-02-01

56
papers

1,300
citations

393982

19
h-index

360668

35
g-index

56
all docs

56
docs citations

56
times ranked

1206
citing authors

#	ARTICLE	IF	CITATIONS
1	Insurance Approval for Definitive Proton Therapy for Prostate Cancer. <i>International Journal of Particle Therapy</i> , 2022, 8, 36-42.	0.9	3
2	Measuring Radiation Toxicity Using Circulating Cell-Free DNA in Prostate Cancer Patients. <i>International Journal of Particle Therapy</i> , 2022, 8, 28-35.	0.9	2
3	Five- and seven-year outcomes for image-guided moderately accelerated hypofractionated proton therapy for prostate cancer. <i>Acta Oncologica</i> , 2022, 61, 468-477.	0.8	1
4	A comparative study of prostate PTV margins for patients using hydrogel spacer or rectal balloon in proton therapy. <i>Physica Medica</i> , 2021, 81, 47-51.	0.4	6
5	Postoperative or Salvage Proton Radiotherapy for Prostate Cancer After Radical Prostatectomy. <i>International Journal of Particle Therapy</i> , 2021, 7, 52-64.	0.9	0
6	Consensus Statement on Proton Therapy for Prostate Cancer. <i>International Journal of Particle Therapy</i> , 2021, 8, 1-16.	0.9	9
7	A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1082-1089.	0.4	19
8	Heterogeneity in Radiotherapeutic Parameter Assumptions in Cost-Effectiveness Analyses in Prostate Cancer: A Call for Uniformity. <i>Value in Health</i> , 2021, 25, 171-177.	0.1	0
9	Image-guided hypofractionated double-scattering proton therapy in the management of centrally-located early-stage non-small cell lung cancer. <i>Acta Oncologica</i> , 2020, 59, 1164-1170.	0.8	6
10	Image-Guided Hypofractionated Proton Therapy in Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Study. <i>International Journal of Particle Therapy</i> , 2020, 7, 1-10.	0.9	6
11	Circulating Cell-Free DNA Correlates with Body Integral Dose and Radiation Modality in Prostate Cancer. <i>International Journal of Particle Therapy</i> , 2020, 7, 21-30.	0.9	1
12	Impact of unfavorable factors on outcomes among inoperable stage II-IV Nonsmall cell lung cancer patients treated with proton therapy. <i>Acta Oncologica</i> , 2019, 58, 313-319.	0.8	2
13	Serum Testosterone 60 Months after Passive-Scatter Proton Therapy for Localized Prostate Cancer. <i>Cancer Investigation</i> , 2019, 37, 85-89.	0.6	5
14	Patient-Reported Sexual Survivorship Following High-Dose Image-Guided Proton Therapy for Prostate Cancer. <i>Radiotherapy and Oncology</i> , 2019, 134, 204-210.	0.3	5
15	Long-term outcomes following proton therapy for prostate cancer in young men with a focus on sexual health. <i>Acta Oncologica</i> , 2018, 57, 582-588.	0.8	17
16	Proton therapy in stage II-IV non-small cell lung cancer: pattern of care and impact on trial accrual. <i>Acta Oncologica</i> , 2018, 57, 692-693.	0.8	5
17	Rectal Culture and Sensitivity Analysis for Reducing Sepsis Risk After Fiducial Marker Placement. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1243-1245.	0.6	1
18	Rationale and early outcomes for the management of thymoma with proton therapy. <i>Translational Lung Cancer Research</i> , 2018, 7, 106-113.	1.3	15

#	ARTICLE	IF	CITATIONS
19	Five-year outcomes from a prospective trial of image-guided accelerated hypofractionated proton therapy for prostate cancer. <i>Acta Oncologica</i> , 2017, 56, 963-970.	0.8	31
20	Sperm preservation and neutron contamination following proton therapy for prostate cancer study. <i>Acta Oncologica</i> , 2017, 56, 17-20.	0.8	6
21	Race Does Not Affect Tumor Control, Adverse Effects, or Quality of Life after Proton Therapy. <i>International Journal of Particle Therapy</i> , 2017, 3, 461-472.	0.9	2
22	A Phase 2 Trial of Concurrent Chemotherapy and Proton Therapy for Stage III Non-Small Cell Lung Cancer: Results and Reflections Following Early Closure of a Single-Institution Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 517-522.	0.4	49
23	Does Race Influence Health-related Quality of Life and Toxicity Following Proton Therapy for Prostate Cancer?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 261-265.	0.6	7
24	Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 422-434.	0.4	90
25	Proton Therapy as Salvage Treatment for Local Relapse of Prostate Cancer Following Cryosurgery or High-Intensity Focused Ultrasound. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 465-471.	0.4	9
26	Patient-Reported Quality of Life in Men with Transurethral Resection of the Prostate Undergoing Proton Therapy for Management of Prostate Cancer. <i>International Journal of Particle Therapy</i> , 2016, 2, 518-524.	0.9	4
27	Bacterial Urinary Tract Infection after Transrectal Placement of Fiducial Markers prior to Proton Radiotherapy for Prostate Cancer. <i>International Journal of Particle Therapy</i> , 2016, 3, 21-26.	0.9	4
28	Controversies in proton therapy for prostate cancer. <i>Chinese Clinical Oncology</i> , 2016, 5, 55-55.	0.4	3
29	Hemorrhagic Radiation Cystitis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 331-336.	0.6	41
30	Rectal Toxicity After Proton Therapy For Prostate Cancer: An Analysis of Outcomes of Prospective Studies Conducted at the University of Florida Proton Therapy Institute. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 172-181.	0.4	41
31	Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. <i>Cancer</i> , 2014, 120, 1076-1082.	2.0	82
32	Salvage of Locally Recurrent Prostate Cancer After Definitive Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 411-416.	0.6	9
33	Management of Radiation Proctitis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 517-523.	0.6	18
34	Five-Year Outcomes from 3 Prospective Trials of Image-Guided Proton Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 596-602.	0.4	103
35	Bacterial Urinary Tract Infection after Fiducial Marker Placement or Prostate Biopsy. <i>International Journal of Particle Therapy</i> , 2014, 1, 745-758.	0.9	2
36	Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: Results of two prospective trials. <i>Acta Oncologica</i> , 2013, 52, 463-469.	0.8	17

#	ARTICLE	IF	CITATIONS
37	Outcomes in men with large prostates ($\geq 60 \text{ cm}^3$) treated with definitive proton therapy for prostate cancer. <i>Acta Oncologica</i> , 2013, 52, 470-476.	0.8	10
38	Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression. <i>Acta Oncologica</i> , 2013, 52, 492-497.	0.8	13
39	When is Elective Pelvic Lymph Node Irradiation Indicated in Definitive Radiotherapy for Localized Prostate Cancer?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 644-647.	0.6	4
40	Androgen Deprivation Therapy and Definitive Radiotherapy for Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 530-534.	0.6	8
41	Patient-reported quality of life in men with TURP undergoing proton therapy for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 220-220.	0.8	1
42	Early Outcomes From Three Prospective Trials of Image-Guided Proton Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 213-221.	0.4	95
43	Proton Radiotherapy for Prostate Cancer Is Not Associated With Post-Treatment Testosterone Suppression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1222-1226.	0.4	20
44	Proton Therapy With Concurrent Chemotherapy for Non-Small-Cell Lung Cancer: Technique and Early Results. <i>Clinical Lung Cancer</i> , 2012, 13, 352-358.	1.1	34
45	Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger. <i>Cancer</i> , 2012, 118, 4619-4626.	2.0	51
46	Proton therapy for lung cancer. <i>Thoracic Cancer</i> , 2012, 3, 109-116.	0.8	10
47	Selective nodal irradiation of regionally advanced non-small-cell lung cancer with proton therapy and IMRT: A dosimetric comparison. <i>Thoracic Cancer</i> , 2012, 3, 169-174.	0.8	4
48	Proton Radiation Therapy Offers Reduced Normal Lung and Bone Marrow Exposure for Patients Receiving Dose-Escalated Radiation Therapy for Unresectable Stage III Non-Small-Cell Lung Cancer: A Dosimetric Study. <i>Clinical Lung Cancer</i> , 2011, 12, 252-257.	1.1	75
49	Protons Safely Allow Coverage of High-Risk Nodes for Patients with Regionally Advanced Non-Small-Cell Lung Cancer. <i>Technology in Cancer Research and Treatment</i> , 2011, 10, 317-322.	0.8	25
50	Is Radical Prostatectomy the "Gold Standard" for Localized Prostate Cancer?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 511-515.	0.6	23
51	Erectile Dysfunction After Radiotherapy for Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 443-447.	0.6	25
52	Postprostatectomy Radiotherapy for Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 529-534.	0.6	5
53	Dose-Volume Comparison of Proton Therapy and Intensity-Modulated Radiotherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 744-751.	0.4	139
54	Prospective Evaluation of Quality of Life and Neurocognitive Effects in Patients With Multiple Brain Metastases Receiving Whole-Brain Radiotherapy With or Without Thalidomide on Radiation Therapy Oncology Group (RTOG) Trial 0118. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 71-78.	0.4	86

#	ARTICLE	IF	CITATIONS
55	Definitive Radiotherapy for Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 496-503.	0.6	24
56	Rectal Doseâ€“Volume Differences Using Proton Radiotherapy andÂaÂRectal Balloon or Water Alone for the Treatment ofÂProstateÂCancer. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1110-1116.	0.4	27